TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER, FULL- YEAR 2019 FINANCIAL AND OPERATIONAL RESULTS
Registrational Phase 2 TRIDENT-1 Study Continues Site Activation and Patient Enrollment Preclinical Data Highlighting Repotrectinib Combinations and Additional Data for TPX-0131 to be Presented in Second Quarter, Given Rescheduling of American Association …